Logo image of PBYI

PUMA BIOTECHNOLOGY INC (PBYI) Stock Fundamental Analysis

NASDAQ:PBYI - Nasdaq - US74587V1070 - Common Stock - Currency: USD

3.72  +0.07 (+1.92%)

After market: 3.71 -0.01 (-0.27%)

Fundamental Rating

5

Overall PBYI gets a fundamental rating of 5 out of 10. We evaluated PBYI against 558 industry peers in the Biotechnology industry. While PBYI belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. PBYI is valued quite cheap, but it does not seem to be growing. This makes PBYI very considerable for value investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

8

1. Profitability

1.1 Basic Checks

PBYI had positive earnings in the past year.
PBYI had a positive operating cash flow in the past year.
In multiple years PBYI reported negative net income over the last 5 years.
PBYI had a positive operating cash flow in 4 of the past 5 years.
PBYI Yearly Net Income VS EBIT VS OCF VS FCFPBYI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M

1.2 Ratios

PBYI's Return On Assets of 19.40% is amongst the best of the industry. PBYI outperforms 96.77% of its industry peers.
Looking at the Return On Equity, with a value of 39.20%, PBYI belongs to the top of the industry, outperforming 98.21% of the companies in the same industry.
The Return On Invested Capital of PBYI (26.87%) is better than 98.92% of its industry peers.
The Average Return On Invested Capital over the past 3 years for PBYI is above the industry average of 14.78%.
The 3 year average ROIC (17.97%) for PBYI is below the current ROIC(26.87%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 19.4%
ROE 39.2%
ROIC 26.87%
ROA(3y)7.85%
ROA(5y)-2.77%
ROE(3y)24.42%
ROE(5y)N/A
ROIC(3y)17.97%
ROIC(5y)N/A
PBYI Yearly ROA, ROE, ROICPBYI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K

1.3 Margins

PBYI has a better Profit Margin (16.36%) than 94.44% of its industry peers.
With an excellent Operating Margin value of 16.01%, PBYI belongs to the best of the industry, outperforming 94.98% of the companies in the same industry.
PBYI's Operating Margin has improved in the last couple of years.
PBYI's Gross Margin of 72.40% is amongst the best of the industry. PBYI outperforms 82.97% of its industry peers.
PBYI's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 16.01%
PM (TTM) 16.36%
GM 72.4%
OM growth 3Y196.89%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.26%
GM growth 5Y-3.58%
PBYI Yearly Profit, Operating, Gross MarginsPBYI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

5

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so PBYI is creating value.
Compared to 1 year ago, PBYI has more shares outstanding
PBYI has more shares outstanding than it did 5 years ago.
PBYI has a better debt/assets ratio than last year.
PBYI Yearly Shares OutstandingPBYI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
PBYI Yearly Total Debt VS Total AssetsPBYI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

PBYI has an Altman-Z score of -6.17. This is a bad value and indicates that PBYI is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of PBYI (-6.17) is worse than 64.34% of its industry peers.
The Debt to FCF ratio of PBYI is 1.80, which is an excellent value as it means it would take PBYI, only 1.80 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 1.80, PBYI belongs to the best of the industry, outperforming 94.62% of the companies in the same industry.
A Debt/Equity ratio of 0.11 indicates that PBYI is not too dependend on debt financing.
PBYI has a Debt to Equity ratio of 0.11. This is in the lower half of the industry: PBYI underperforms 66.67% of its industry peers.
Even though the debt/equity ratio score it not favorable for PBYI, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF 1.8
Altman-Z -6.17
ROIC/WACC2.44
WACC11.02%
PBYI Yearly LT Debt VS Equity VS FCFPBYI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M -200M

2.3 Liquidity

PBYI has a Current Ratio of 1.53. This is a normal value and indicates that PBYI is financially healthy and should not expect problems in meeting its short term obligations.
PBYI has a worse Current ratio (1.53) than 81.36% of its industry peers.
PBYI has a Quick Ratio of 1.43. This is a normal value and indicates that PBYI is financially healthy and should not expect problems in meeting its short term obligations.
PBYI has a worse Quick ratio (1.43) than 81.72% of its industry peers.
Industry RankSector Rank
Current Ratio 1.53
Quick Ratio 1.43
PBYI Yearly Current Assets VS Current LiabilitesPBYI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

2

3. Growth

3.1 Past

PBYI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 133.33%, which is quite impressive.
PBYI shows a small growth in Revenue. In the last year, the Revenue has grown by 2.68%.
PBYI shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -3.28% yearly.
EPS 1Y (TTM)133.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%160%
Revenue 1Y (TTM)2.68%
Revenue growth 3Y-3.09%
Revenue growth 5Y-3.28%
Sales Q2Q%5.02%

3.2 Future

PBYI is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -30.07% yearly.
Based on estimates for the next years, PBYI will show a decrease in Revenue. The Revenue will decrease by -1.09% on average per year.
EPS Next Y-32.84%
EPS Next 2Y-19.11%
EPS Next 3Y-9.04%
EPS Next 5Y-30.07%
Revenue Next Year-2.74%
Revenue Next 2Y-1.59%
Revenue Next 3Y-0.56%
Revenue Next 5Y-1.09%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
PBYI Yearly Revenue VS EstimatesPBYI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M 150M 200M 250M
PBYI Yearly EPS VS EstimatesPBYI Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 -2 -4 -6 -8

More info and screens

8

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 4.83, the valuation of PBYI can be described as very cheap.
Based on the Price/Earnings ratio, PBYI is valued cheaper than 98.92% of the companies in the same industry.
PBYI's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.52.
Based on the Price/Forward Earnings ratio of 9.32, the valuation of PBYI can be described as reasonable.
Based on the Price/Forward Earnings ratio, PBYI is valued cheaper than 96.77% of the companies in the same industry.
PBYI is valuated cheaply when we compare the Price/Forward Earnings ratio to 22.25, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 4.83
Fwd PE 9.32
PBYI Price Earnings VS Forward Price EarningsPBYI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, PBYI is valued cheaply inside the industry as 99.28% of the companies are valued more expensively.
PBYI's Price/Free Cash Flow ratio is rather cheap when compared to the industry. PBYI is cheaper than 98.92% of the companies in the same industry.
Industry RankSector Rank
P/FCF 5.92
EV/EBITDA 2.34
PBYI Per share dataPBYI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 1 2 3 4

4.3 Compensation for Growth

The excellent profitability rating of PBYI may justify a higher PE ratio.
PBYI's earnings are expected to decrease with -9.04% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-19.11%
EPS Next 3Y-9.04%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PBYI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PUMA BIOTECHNOLOGY INC

NASDAQ:PBYI (6/6/2025, 8:18:36 PM)

After market: 3.71 -0.01 (-0.27%)

3.72

+0.07 (+1.92%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)07-30 2025-07-30
Inst Owners67.9%
Inst Owner Change18.17%
Ins Owners15.64%
Ins Owner Change3.46%
Market Cap184.66M
Analysts47.5
Price Target4.42 (18.82%)
Short Float %6.84%
Short Ratio8.56
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)333.26%
Min EPS beat(2)272.41%
Max EPS beat(2)394.12%
EPS beat(4)4
Avg EPS beat(4)178.28%
Min EPS beat(4)14.63%
Max EPS beat(4)394.12%
EPS beat(8)7
Avg EPS beat(8)170%
EPS beat(12)10
Avg EPS beat(12)263.94%
EPS beat(16)13
Avg EPS beat(16)206.37%
Revenue beat(2)2
Avg Revenue beat(2)5.8%
Min Revenue beat(2)1.23%
Max Revenue beat(2)10.36%
Revenue beat(4)4
Avg Revenue beat(4)6.65%
Min Revenue beat(4)1.23%
Max Revenue beat(4)11.71%
Revenue beat(8)6
Avg Revenue beat(8)3.23%
Revenue beat(12)10
Avg Revenue beat(12)5.39%
Revenue beat(16)11
Avg Revenue beat(16)3.94%
PT rev (1m)26.92%
PT rev (3m)26.92%
EPS NQ rev (1m)-20%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0.42%
EPS NY rev (3m)18.25%
Revenue NQ rev (1m)-3.79%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)4.76%
Valuation
Industry RankSector Rank
PE 4.83
Fwd PE 9.32
P/S 0.79
P/FCF 5.92
P/OCF 5.9
P/B 1.9
P/tB 3.81
EV/EBITDA 2.34
EPS(TTM)0.77
EY20.7%
EPS(NY)0.4
Fwd EY10.73%
FCF(TTM)0.63
FCFY16.88%
OCF(TTM)0.63
OCFY16.94%
SpS4.69
BVpS1.96
TBVpS0.98
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 19.4%
ROE 39.2%
ROCE 34.01%
ROIC 26.87%
ROICexc 179.97%
ROICexgc N/A
OM 16.01%
PM (TTM) 16.36%
GM 72.4%
FCFM 13.39%
ROA(3y)7.85%
ROA(5y)-2.77%
ROE(3y)24.42%
ROE(5y)N/A
ROIC(3y)17.97%
ROIC(5y)N/A
ROICexc(3y)84.91%
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)22.75%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3Y271.17%
ROICexc growth 5YN/A
OM growth 3Y196.89%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.26%
GM growth 5Y-3.58%
F-Score6
Asset Turnover1.19
Health
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF 1.8
Debt/EBITDA 0.22
Cap/Depr 1.02%
Cap/Sales 0.05%
Interest Coverage 3.81
Cash Conversion 64.28%
Profit Quality 81.87%
Current Ratio 1.53
Quick Ratio 1.43
Altman-Z -6.17
F-Score6
WACC11.02%
ROIC/WACC2.44
Cap/Depr(3y)62.9%
Cap/Depr(5y)77.72%
Cap/Sales(3y)2.82%
Cap/Sales(5y)3.47%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)133.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%160%
EPS Next Y-32.84%
EPS Next 2Y-19.11%
EPS Next 3Y-9.04%
EPS Next 5Y-30.07%
Revenue 1Y (TTM)2.68%
Revenue growth 3Y-3.09%
Revenue growth 5Y-3.28%
Sales Q2Q%5.02%
Revenue Next Year-2.74%
Revenue Next 2Y-1.59%
Revenue Next 3Y-0.56%
Revenue Next 5Y-1.09%
EBIT growth 1Y39.99%
EBIT growth 3Y187.73%
EBIT growth 5YN/A
EBIT Next Year45.92%
EBIT Next 3Y3.72%
EBIT Next 5YN/A
FCF growth 1Y638.29%
FCF growth 3Y23.46%
FCF growth 5Y11.98%
OCF growth 1Y128.18%
OCF growth 3Y23.52%
OCF growth 5Y11.7%